BioInvent International AB (publ) (BOVNF) Financials

BOVNF Assets vs Liabilities

DateAssetsLiabilities
June 30, 2026 43.3 million 10.9 million
March 31, 2026 55.9 million 10.0 million
Dec. 31, 2025 72.7 million 12.3 million
Sept. 30, 2025 82.9 million 10.8 million

BOVNF Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -11.5 million ?
March 31, 2026 -13.9 million 71662
Dec. 31, 2025 -9.9 million 45723
Sept. 30, 2025 -11.1 million ?

BOVNF Net Income

No data available :(

BOVNF Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 34.8 million - 1.3 million
March 31, 2026 47.7 million - 653420
Dec. 31, 2025 64.2 million 125343 925782
Sept. 30, 2025 72.8 million - 167960

BOVNF Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 6.8 million
March 31, 2026 6.9 million
Dec. 31, 2025 7.2 million
Sept. 30, 2025 7.0 million

BOVNF Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 66367 12.3 million 1.3 million -
March 31, 2026 65916 12.3 million 1.8 million -
Dec. 31, 2025 138559 12.2 million 1.7 million -
Sept. 30, 2025 212339 12.6 million 1.4 million -

BOVNF Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 1.3 million -
March 31, 2026 1.4 million -
Dec. 31, 2025 326738 -
Sept. 30, 2025 350147 -

BOVNF

Price: $3.29

52 week price:
3.29
4.70

Earnings Per Share: -0.47 USD

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 216.4 million

Links: